N
News Analysis
prnewswire.com

www.prnewswire.com ·

Negative

sophia genetics reports first quarter 2026 results 302761826

TAX_FNCACT_CHIEF_EXECUTIVE_OFFICERTAX_RELIGION_CHRISTIANTAX_ETHNICITY_CHRISTIANECON_ENTREPRENEURSHIP

All NewsRead the full story on prnewswire.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

SOPHiA GENETICS is a genomics data analysis company. Revenue growth driven by volume increase (16% more analyses) and customer expansion (537 core genomics customers). Gross margin stable at 68%. Net loss widening indicates ongoing investment. No direct commodity or supply chain scarcity; impact is company-specific. Sector: PHARMA_BIOTECH (genomics services) and GLOBAL_HEALTHCARE (diagnostics).

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Revenue $21.7M, +22% YoY
  • Gross margin 68.0%
  • IFRS net loss $19.3M, +11% YoY
  • Record 108,000 genomic analyses, +16% volume
  • FY2026 revenue guidance $92-94M, +20-22%
sophia genetics reports first quarter 2026 results 302761826 | prnewswire.com — News Analysis